China National Medicines Corporation Ltd. (SHA:600511)
28.70
-0.08 (-0.28%)
Mar 26, 2026, 2:04 PM CST
SHA:600511 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 52,468 | 50,500 | 49,592 | 45,436 | 46,442 |
Other Revenue | - | 97.79 | 103.99 | 62.95 | 26.26 |
| 52,468 | 50,597 | 49,696 | 45,499 | 46,469 | |
Revenue Growth (YoY) | 3.70% | 1.81% | 9.22% | -2.09% | 15.08% |
Cost of Revenue | 49,008 | 47,003 | 45,704 | 41,681 | 42,848 |
Gross Profit | 3,460 | 3,594 | 3,992 | 3,817 | 3,621 |
Selling, General & Admin | 1,190 | 1,267 | 1,430 | 1,392 | 1,355 |
Research & Development | 69.31 | 73.71 | 71.2 | 67 | 55.75 |
Other Operating Expenses | 128.16 | 126.25 | 109.69 | 46.91 | 120.86 |
Operating Expenses | 1,387 | 1,489 | 1,620 | 1,498 | 1,566 |
Operating Income | 2,072 | 2,105 | 2,372 | 2,319 | 2,055 |
Interest Expense | - | -33.66 | -31.57 | -26.88 | -43.71 |
Interest & Investment Income | 566.78 | 620.95 | 525.32 | 362.42 | 354.09 |
Currency Exchange Gain (Loss) | - | 1.94 | 0.55 | -1.65 | 2.71 |
Other Non Operating Income (Expenses) | -33.74 | -7.04 | -9.23 | -43.29 | -18 |
EBT Excluding Unusual Items | 2,605 | 2,687 | 2,857 | 2,609 | 2,350 |
Gain (Loss) on Sale of Investments | 0.07 | -18.2 | 10.82 | - | - |
Gain (Loss) on Sale of Assets | 0.21 | -0.19 | 0.08 | 1.68 | -0.07 |
Asset Writedown | -5.56 | - | - | - | - |
Other Unusual Items | - | -14.9 | 62.81 | 76.9 | 95.08 |
Pretax Income | 2,600 | 2,654 | 2,931 | 2,688 | 2,445 |
Income Tax Expense | 510.74 | 523.83 | 596.42 | 559.18 | 516.3 |
Earnings From Continuing Operations | 2,089 | 2,130 | 2,334 | 2,129 | 1,929 |
Minority Interest in Earnings | -92.81 | -129.65 | -188.47 | -164.65 | -174.42 |
Net Income | 1,997 | 2,000 | 2,146 | 1,964 | 1,754 |
Net Income to Common | 1,997 | 2,000 | 2,146 | 1,964 | 1,754 |
Net Income Growth | -0.18% | -6.80% | 9.26% | 11.97% | 26.86% |
Shares Outstanding (Basic) | 755 | 755 | 754 | 755 | 755 |
Shares Outstanding (Diluted) | 755 | 755 | 754 | 755 | 755 |
Shares Change (YoY) | 0.00% | 0.00% | -0.00% | - | 0.00% |
EPS (Basic) | 2.65 | 2.65 | 2.84 | 2.60 | 2.32 |
EPS (Diluted) | 2.65 | 2.65 | 2.84 | 2.60 | 2.32 |
EPS Growth | -0.18% | -6.80% | 9.27% | 11.97% | 26.86% |
Free Cash Flow | 1,937 | 1,528 | 2,582 | 2,265 | 1,862 |
Free Cash Flow Per Share | 2.57 | 2.03 | 3.42 | 3.00 | 2.47 |
Dividend Per Share | - | 0.800 | 0.854 | 0.782 | 0.700 |
Dividend Growth | - | -6.32% | 9.21% | 11.71% | 27.27% |
Gross Margin | 6.59% | 7.10% | 8.03% | 8.39% | 7.79% |
Operating Margin | 3.95% | 4.16% | 4.77% | 5.10% | 4.42% |
Profit Margin | 3.81% | 3.95% | 4.32% | 4.32% | 3.77% |
Free Cash Flow Margin | 3.69% | 3.02% | 5.20% | 4.98% | 4.01% |
EBITDA | 2,200 | 2,215 | 2,485 | 2,423 | 2,155 |
EBITDA Margin | 4.19% | 4.38% | 5.00% | 5.32% | 4.64% |
D&A For EBITDA | 127.66 | 110.03 | 113.09 | 103.86 | 100.1 |
EBIT | 2,072 | 2,105 | 2,372 | 2,319 | 2,055 |
EBIT Margin | 3.95% | 4.16% | 4.77% | 5.10% | 4.42% |
Effective Tax Rate | 19.64% | 19.74% | 20.35% | 20.80% | 21.12% |
Revenue as Reported | - | 50,597 | 49,696 | 45,499 | 46,469 |
Advertising Expenses | - | 4.74 | 6.7 | 3.25 | 2.25 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.